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BACKGROUND. African-American men have a greater incidence of and mortality
from prostate carcinoma compared with white men, and they are less likely to
receive definitive therapy (radical prostatectomy or external beam radiation ther-
apy). During the 1990s, the use of brachytherapy increased; however, its influence
on racial and ethnic prostate carcinoma treatment trends remains unclear. The
objective of this study was to describe treatment trends over the period 1992–1999
for localized/regional prostate carcinoma among white, Hispanic, and African-
American men.
METHODS. Using the Surveillance, Epidemiology, and End Results (SEER) registry
data from 1992 through 1999, logistic regression models were used to determine
whether the odds of receiving a specific treatment modality differed by racial and
ethnic group and whether the differences changed over time when the models
were adjusted for age, marital status, tumor grade, and SEER site (geography).
RESULTS. The authors identified 142,340 men, including white men (81.6%), His-
panic men (6.4%), and African-American men (12.0%). Racial and ethnic differ-
ences in the rates of use of androgen-deprivation therapy/expectant management
were noted; however, these differences appeared to lessen over time (P  0.001).
The rate of utilization of radical prostatectomy increased for Hispanic men, re-
mained flat for African-American men, and decreased for white men. The utiliza-
tion of brachytherapy and combination therapy increased for all three groups;
however, the greatest increase in utilization was among white men.
CONCLUSIONS. Further research will be required to determine the patient-level and
provider-level variables that influence racial and ethnic treatment differences in
localized/regional prostate cancer. Cancer 2005;103:538 – 45.
© 2004 American Cancer Society.
KEYWORDS: African American, Hispanic, white, brachytherapy, radical prostatec-
tomy, external beam radiation therapy, prostate carcinoma, prostate carcinoma
treatment, combination therapy.
Prostate carcinoma is the most prevalent noncutaneous malig-nancy in American men. It is projected that there were 220,900
incident diagnoses of prostate carcinoma and 28,900 deaths in the
United States in 2003, accounting for 30% of all newly diagnosed
malignancies.1 Compared with white men, African-American men
have a greater incidence and mortality from prostate carcinoma,1,2
they are diagnosed with higher grade/stage prostate carcinomas, and
they are less likely to receive definitive therapy (radical prostatectomy
or external beam radiation therapy).3– 6
Schapira et al.3 reported a significant racial difference in the
utilization of specific treatment modalities for the treatment of local-
ized prostate carcinoma. Using data from the Surveillance, Epidemi-
ology, and End Results (SEER) registry between 1988 and 1989, they
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reported that African-American men were less likely to
receive definitive therapy (radical prostatectomy or
external beam radiation therapy) when diagnosed
with localized prostate carcinoma. In addition, if men
received definitive therapy, then they were less likely
to undergo radical prostatectomy. Other investigators
have reported similar findings.4 – 6 Those studies doc-
umented clear racial differences in the utilization of
specific treatment modalities for localized/regional
prostate carcinoma. During the 1990s, the use of
brachytherapy increased, and there was an effort to
promote prostate cancer education, earlier detection,
and definitive treatment among African-American
men.7,8 The influence of those factors on racial and
ethnic prostate carcinoma treatment trends remains
unclear.
In contrast to the clear racial differences found in
treatment for prostate carcinoma between African-
American men and white men, little has been pub-
lished regarding Hispanic men. However, Hispanics
comprise 6% of the United States population, and they
are the largest growing minority group. Although stud-
ies have described an increase in mortality from pros-
tate carcinoma in this population,9 –11 treatment
trends in the Hispanic community have not been well
documented. The objective of this study was to de-
scribe racial and ethnic trends from 1992 through 1999
in the utilization of specific treatment modalities (an-
drogen-deprivation therapy [ADT]/expectant manage-
ment, radical prostatectomy, external beam radiation
therapy, brachytherapy, and combination therapy) for
localized/regional prostate carcinoma among white,
Hispanic, and African-American men using data from
the national SEER registry.
MATERIALS AND METHODS
Setting
The National Cancer Institute developed and main-
tains the SEER Program, a population-based cancer
program, to collect incidence, treatment, and cancer
mortality data.12 SEER encompasses approximately
14% of the United States population from 11 defined
geographic regions, including 5 states (Connecticut,
Hawaii, Iowa, New Mexico, and Utah) and 6 metro-
politan regions (San Francisco-Oakland, Metropolitan
Detroit, Metropolitan Atlanta, San Jose-Monterey, Se-
attle-Puget Sound, and Los Angeles).13 SEER cancer
incidence, mortality, and demographic data generally
are representative of the national population.13,14 Data
collected within SEER predominately are hospital-
based inpatient and outpatient data, but they also
include physician office, nursing/convalescent home/
hospice, autopsy, and death certificate information.
SEER explicitly reviews diagnoses from hospital dis-
charge reports, pathology reports, and death certifi-
cates. Data accuracy and completeness are evaluated
through a routine quality-control program.13 Patient
demographics, disease stage, first course of therapy,
and survival data are available from the SEER regis-
tries.12
Identification of Patients with Prostate Carcinoma
To evaluate racial and ethnic trends in the utilization
of specific therapies for localized/regional prostate
carcinoma, data were abstracted from the available
SEER public-use tapes and all incident diagnoses (n
 161,289 men) of localized/regional prostate carci-
noma (International Classification of Diseases, ninth
revision; code 185) histologically identified as adeno-
carcinoma (International Classification of Diseases for
Oncology, second revision; code 8140/3) were identi-
fied. SEER defines localized disease as invasive carci-
noma of any size confined to the organ of origin and
defines regional disease as extending beyond the lim-
its of the organ or origin and/or involving the regional
lymph nodes but excluding distant lymph nodes.12
Within SEER, the most complete staging information
is used, incorporating data from pathologic (i.e., rad-
ical prostatectomy) and clinical staging.12 In addition,
within SEER, individual race identity is determined
from self-reported demographic information within
medical records.12 Of the previously identified inci-
dent diagnoses, we excluded 5482 men (3.4%) due to a
lack of data on race and/or treatment received, and we
excluded 5351 men (3.3%) due to a lack of tumor grade
information. The 3 largest racial and ethnic groups
from SEER are white, Hispanic, and African American,
accounting for 94.6% of the sample. For the purpose of
this report, we restricted our analysis to these three
groups. In this manner, we identified 142,340 men
who were diagnosed with localized/regional prostate
carcinoma, including 116,132 white men (81.6%), 9121
Hispanic men (6.4%), and 17,087 African-American
men (12.0%).
Definition of Interventions
The proportion of men whose first course of therapy
was ADT/expectant management, surgery, external
beam radiation therapy, brachytherapy, or some com-
bination was determined. Within SEER, the first
course of therapy is defined as all disease-directed
therapy within 4 months after the initial diagnosis and
all planned therapy within the first year, as indicated
in the medical record. We defined radical prostatec-
tomy as undergoing surgery with curative intent; men
who underwent transurethral resection of the prostate
and other noncurative procedures were not included
in the radical prostatectomy group. SEER does not
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contain information on the dose of radiation or
whether the full course of therapy was completed;
therefore, we defined external beam radiation therapy
as the receipt of any external beam radiation. We
defined brachytherapy as the receipt of radiation im-
plants (seeds) or radioisotopes. We defined combina-
tion therapy as the receipt of any combination of
radical prostatectomy, external beam radiation ther-
apy, or brachytherapy. The ADT/expectant manage-
ment group consisted of all other individuals who
were not classified otherwise in the radical prostatec-
tomy, external beam radiation therapy, brachyther-
apy, or combination therapy groups. Information on
the utilization of ADT is not available in the public-use
national SEER data set; therefore, men who received
only ADT were included in the ADT/expectant man-
agement group.
Statistical Analysis
The primary outcome measure in this study was the
utilization of definitive therapies for localized/re-
gional stage prostate carcinoma among men who were
diagnosed between 1992 and 1999. Chi-square analy-
ses were performed to ascertain possible differences
between racial and ethnic groups in the distribution of
marital status, tumor grade, and treatment received
(ADT/expectant management, radical prostatectomy,
external beam radiation therapy, brachytherapy, or
combination therapy). An analysis of variance was
used to examine age differences by race and ethnicity.
Logistic regression models were used to assess
whether the odds of receiving a specific treatment
modality differed by racial and ethnic group and
whether the differences between racial and ethnic
groups changed over time, adjusting for age, marital
status, tumor grade, and SEER site (geography). The
change in racial and ethnic differences over time was
addressed by including racial and ethnic group by
diagnosis year interaction terms in the model. A back-
ward model-selection procedure was used to obtain
the most parsimonious models. In addition, log-linear
modeling was used to generate estimates of the dis-
tribution of race and ethnicity by treatment adjusted
for age group ( 50 years, 50 –59 years, 60 – 69 years,
70 –79 years, and  80 years), marital status, tumor
grade, and SEER site. All statistical analyses were per-
formed using SAS software (SAS Institute, Inc., Cary,
NC). The level of significance for all statistical analysis
was set at P  0.05.
RESULTS
Cohort Characteristics
Among all 142,340 men in the cohort, 81.6% were
white, 6.4% were Hispanic, and 12.0% were African
American. Compared with Hispanic and white men,
African-American men were diagnosed at a signifi-
cantly younger age. They also were diagnosed in
greater proportion with moderate and poorly differen-
tiated tumors, and they were married in lower propor-
tion (Table 1).
Racial and Ethnic Differences in Treatment
We determined the adjusted estimates of receiving a
specific treatment modality between 1992 and 1999
stratified by race and ethnicity. In this model, esti-
mates were adjusted for age, marital status, tumor
grade, and SEER site (Table 2). Of the treatment mo-
dalities evaluated, white and Hispanic men were more
likely to undergo radical prostatectomy, whereas Afri-
can-American men were more likely to receive ADT/
expectant management (P  0.001). Compared with
white men, Hispanic and African-American men were
significantly more likely to receive ADT/expectant
management (P  0.001). Hispanic men were more
likely to undergo radical prostatectomy than both
white and African-American men (P  0.001). Com-
pared with white and Hispanic men, African-Ameri-
can men were more likely to receive external beam
TABLE 1
Distribution of Age and Grade by Race and Ethnicitya
Characteristic Total sample White Hispanic African-American P value
No. of patients (%) 142,340 (100.0) 116,132 (81.6) 9121 (6.4) 17,087 (12.0) —
Age in yrs (mean  SD) 68.6  8.8 68.9  8.7 68.1  8.6 66.5  9.0  0.001
Married (%) 78.6 80.8 77.3 64.3  0.001
Tumor grade (%)  0.001
Well differentiated 13.1 13.3 14.9 11.0
Moderately differentiated 67.7 67.9 64.6 68.0
Poorly differentiated 19.2 18.8 20.5 21.0
SD: standard deviation.
a Chi-square analysis was used to compare distribution across races, except for age, for which an analysis of variance was used.
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radiation therapy (P  0.001). Compared with the
other treatment modalities, among the 3 groups,
brachytherapy was used the least; however, white men
were most likely, and Hispanic men were least likely,
to receive brachytherapy (P  0.001). Although the
proportion of our cohort that received combination
therapy was relatively low, compared with Hispanic
and African-American men, white men were more
likely to receive combination therapy (P  0.001).
Changes Over Time
To determine whether the utilization of specific treat-
ment modalities for localized/regional prostate carci-
noma changed over the study period, we examined
the adjusted trends in utilization of ADT/expectant
management, radical prostatectomy, external beam
radiation therapy, brachytherapy, and combination
therapy per 1000 men with prostate carcinoma who
were diagnosed between 1992 and 1999, stratified by
race and ethnicity (Fig. 1). Within the study cohort, the
utilization of ADT/expectant management decreased
significantly over time (P  0.001). Racial and ethnic
differences in the rates of use of ADT/expectant man-
agement were found; however, those differences ap-
peared to diminish over time. In 1992, white men
received ADT/expectant management at a rate that
was statistically significantly lower compared with
Hispanic and African-American men. Although the
racial and ethnic differences in the utilization of ADT/
expectant management improved by 1999, white men
still had significantly lower utilization rates than Afri-
can-American men. However, in 1999, the utilization
of ADT/expectant management was not statistically
significantly different between white men and His-
panic men (Fig. 1A).
Throughout the study period, the rate of utiliza-
tion of radical prostatectomy increased for Hispanic
men, remained relatively flat for African-American
men, and generally decreased for white men. Overall,
Hispanic men had the highest rate of utilization of
radical prostatectomy, and African-American men had
the highest rate of utilization of external beam radia-
tion therapy (Table 2). The rate utilization of external
beam radiation therapy generally increased for His-
panic men and generally decreased for African-Amer-
ican and white men; such that, by 1999, differences in
the use of external beam radiation therapy for white,
Hispanic, and African-American men were not statis-
tically significant. (P  0.05) (Fig. 1C). Although the
rates of use of brachytherapy and combination ther-
apy were low, they increased for white, Hispanic, and
African-American men between 1995 and 1999. It is
noteworthy that white men had the highest rates and
Hispanic men had the lowest rates of utilization of
both brachytherapy and combination therapy (P
 0.001) (Fig, 1D,E).
DISCUSSION
In the current study, we examined racial and ethnic
differences in the utilization of specific treatment mo-
dalities by men diagnosed with localized/regional
prostate carcinoma. We found that, compared with
white men, Hispanic and African-American men were
more likely to receive ADT/expectant management.
Consistently, African-American men were more likely
to receive ADT/expectant management and external
beam radiation therapy and were less likely to un-
dergo radical prostatectomy compared with white and
Hispanic men. This is in agreement with the results of
Schapira et al.,3 who found that African-American
men were 46% as likely as white men to undergo
radical prostatectomy or receive external beam radia-
tion therapy. Those authors also reported that, among
men who either underwent radical prostatectomy or
received external beam radiation therapy, African-
American men were 64% less likely than white men to
undergo radical prostatectomy. Harlan et al.,15 in a
later study, reported that African-American men age
 60 years underwent aggressive treatment (radical
prostatectomy or external beam radiation therapy)
less often than white or Hispanic men. There are a
growing number of studies that find racial differences
in the receipt of major therapeutic procedures for a
broad range of conditions, even after adjustment for
insurance status, economic status, and severity of dis-
ease.16 –18
Given the lack of scientific data of the best specific
TABLE 2
Log-Linear Adjusted Estimates of Distribution of Specific Treatment







management 29.6 33.4 34.5  0.001
Radical prostatectomy 36.7 40.1 31.7
External beam radiation 23.8 20.7 26.0
Brachytherapy 3.8 1.5 2.3
Combination therapy 6.1 4.3 5.5
ADT: androgen-deprivation therapy.
Log-linear regression models adjusted for age, marital status, tumor grade, and SEER site (geography)
were used to determine the adjusted estimates of use of specific treatments across racial and ethnic
groups. All pairwise comparisons between racial treatment distributions were statistically significant at
P  0.001.
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FIGURE 1. Trends of utilization of androgen-deprivation therapy (ADT)/expectant management (A), radical prostatectomy (B), external beam radiation therapy (C),
brachytherapy (D), and combination therapy (E) stratified by race and ethnicity for white, Hispanic, and African-American patients with prostate carcinoma (CaP)
for the period 1992–1999. Logistic regression analyses were used to determine whether the odds of receiving ADT/expectant management, radical prostatectomy,
external beam radiation therapy, brachytherapy, or combination therapy differed by racial and ethnic group and whether the differences between racial and ethnic
groups changed over time, adjusted for age, marital status, tumor grade, and SEER site. The changes in racial and ethnic differences over time were determined
by including race/ethnic group by year of diagnosis interaction terms in the model.
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treatment modality for localized/regional prostate
carcinoma, treatment decision-making can be difficult
both for patients and for providers. Patient-level vari-
ables (e.g., socioeconomic status, preferences toward
treatment outcomes, and trust in the healthcare sys-
tem) and provider-level variables (e.g., clinician biases
toward specific treatment recommendations and the
lack of clinician agreement on what information is
essential in making a treatment decision) are possible
confounders in the treatment decision-making pro-
cess for men with localized/regional prostate carcino-
ma.19 –30 Therefore, it is important to improve our
understanding of how patient-level and provider-level
variables may confound patient racial and ethnic dif-
ferences in the treatment received for localized/re-
gional prostate carcinoma.
Patient-Level Variables
The outcomes reported here, as noted above, should
be interpreted with respect to the influence of pa-
tients’ socioeconomic status, preferences toward
treatment outcomes, and trust in the healthcare sys-
tem. Because race/ethnicity and socioeconomic posi-
tion are intertwined closely, it is difficult to determine
the extent to which the reported racial and ethnic
healthcare differences are due to differences in socio-
economic status.31 Morris et al.19 evaluated racial and
ethnic differences in the use of radical prostatectomy,
adjusting for socioeconomic status. They reported
that, compared with white men, African-American
men were less likely, and Hispanic men were equally
as likely, to undergo radical prostatectomy. Those au-
thors concluded that, although differences in socio-
economic status influenced treatment received (with
men of lower income levels less likely to undergo
radical prostatectomy), they did not explain entirely
the differences found between African-American men
and white men.
Racial and ethnic differences in the preference
toward treatment outcomes are not well understood.
Steginga et al.32 reported that prostate carcinoma
treatment decisions were influenced primarily by
nonsystematic decision processes, such as deferral to
physicians’ recommendation, the positive and nega-
tive experiences of others, and preexisting belief that
surgery is a better treatment for prostate carcinoma.
When patients did utilize a systematic approach, how-
ever, they most commonly reported incontinence
(55%) and impotence (51%) from surgery and bowel
problems (30%) and skin burning (21%) from radia-
tion therapy as factors that influenced their treatment
decision. O’Rouke and Germino,33 in a focus group
study, reported that beliefs about cancer and possible
cures were major factors in the treatment decisions
among men and their spouses who had been treated
previously for localized prostate carcinoma. Although
those studies have contributed to our understanding
of the patient-level variables that influence treatment
decisions, they did not include racially and ethnically
diverse populations. Therefore, it is unknown whether
the findings to date are the result of racial and ethnic
differences in risk aversion to treatment side effects,
beliefs about cancer and cure, or historic experiences
in the healthcare system that influence treatment
preferences.
Racial and ethnic differences regarding mistrust of
the healthcare system are well documented.25,34 Cor-
bie-Smith et al.25 reported that African Americans
were more likely than whites not to trust that their
physicians would explain research participation fully.
Those authors also reported that African Americans
were more likely to believe that their physician some-
times exposed them to unnecessary risks and used
them as “guinea pigs” without their consent. Very little
is known about racial and ethnic differences in mis-
trust of physicians and prostate carcinoma treatment.
Based on the general literature, it is reasonable to
speculate that minority patients’ mistrust may result
in greater refusal of more invasive procedures, such as
radical prostatectomy. It should be noted, however,
that, irrespective of the higher level of reported mis-
trust of the medical community by racial and ethnic
minorities, most of these patients are satisfied with
and have confidence in their healthcare providers.34,35
Furthermore, mistrust or perceived discrimination
alone reportedly is unlikely to cause ethnic minority
patients to reject lifesaving or highly recommended
procedures that promise to improve health.34 Further
research is needed in this area to determine the pos-
sible influence of patient mistrust in the treatment of
localized/regional prostate carcinoma, particularly as
it relates to Hispanic and African-American men.
Provider-Level Variables
Due to the lack of a randomized clinical trial showing
a clear survival advantage for any given treatment,
objectively advising patients in the optimal treatment
for localized/regional prostate carcinoma is difficult.
The lack of evidence for an optimal treatment modal-
ity may contribute to the findings of Fowler et al.,29
who reported that radiation oncologists and urologists
tended to recommend the therapy that they them-
selves deliver. In a head-to-head comparison of sur-
gery versus external beam radiation therapy, urolo-
gists overwhelmingly reported that surgery was
better.29 Urologists and radiation oncologists not only
disagree on which prostate treatment is best, they also
disagree on what information should be discussed
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with the patients during consultation for prostate car-
cinoma treatment.28 These reported disagreements
among physicians imply that clinicians may be impos-
ing their own personal values when making treatment
recommendations and when deciding what informa-
tion should be discussed with the patient. It is un-
known whether these clinician treatment biases are
influenced by patients’ race and ethnicity or the pos-
sible affect on clinical practice. Therefore, it is difficult
to determine the extent, if any, to which these re-
ported clinician biases have contributed to racial and
ethnic differences in prostate carcinoma treatment.
Another factor that may influence racial and eth-
nic differences in the utilization of ADT/expected
management, radical prostatectomy, and external
beam radiation therapy is the increased utilization of
brachytherapy and combination therapy during the
study period. The overall utilization of brachytherapy
was low: 3.8% among white men, 1.5% among His-
panic men, and 2.3% among African-American men.
The rates of utilization, however, increased signifi-
cantly from 1992 to 1999 for all 3 groups. These results
are consistent with the findings of Mettlin et al.,7 who
reported an increase in the utilization of brachyther-
apy from 1992 to 1996. The use of ADT/expectant
management decreased from 1994 to 1999 for the 3
groups. During the same period, white men had de-
creased utilization of radical prostatectomy and exter-
nal beam radiation therapy and had increased utiliza-
tion of combination therapy and brachytherapy. It
appears that, for white men, brachytherapy may have
influenced significantly the decline in the use of ADT/
expectant management, radical prostatectomy, and
external beam radiation therapy from 1994 through
1999.
Although the selection of brachytherapy showed
an overall increase during the study period, it showed
the greatest increase among white men. It is claimed
that the efficacy of brachytherapy is equivalent to that
of external beam radiation therapy and radical pros-
tatectomy in men who have a low risk of biochemical
failure (prostate-specific antigen  10 ng/mL and
Gleason score  6).36 However, African-American and
Hispanic men within the current study population
had a higher proportion of poor-grade tumors; possi-
bly making brachytherapy a less ideal treatment mo-
dality for many of them. Thus, our findings of lower
utilization of brachytherapy by African-American and
Hispanic men may be the result of clinical parameter-
appropriate utilization of brachytherapy.
In interpreting the results of the current study,
several limitations should be considered. First, within
SEER, treatment is defined as received or planned to
receive within the first year of diagnosis. Thus, delays
in treatment due to neoadjuvant ADT beyond this
time may be misclassified as ADT/expectant manage-
ment. This is unlikely, however, because the typical
use of neoadjuvant ADT is only 3– 6 months. There-
fore, subsequent intent to receive a specific definitive
therapy should have been identified by SEER as
planned in the first year after diagnosis. Second, dif-
ferential rates of the utilization of radical prostatec-
tomy among African-American men may be second-
ary to higher rates of positive lymph nodes during
radical prostatectomy and subsequent abortion of
procedure. Such patients would be captured only as
ADT/expectant management, resulting in potential
bias. To examine this further, we performed a second-
ary analysis on respondents from 1998 and 1999, for
which there were available SEER data on pelvic lymph
dissection, to evaluate for any racial and ethnic dis-
parities among men who underwent pelvic lymph
node dissection without radical prostatectomy. In that
analysis, we did not observe significant differences
among racial or ethnic groups (P  0.05); therefore, it
is unlikely that our findings of lower rates of use of
radical prostatectomy by African-American men were
influenced by higher rates of positive lymph nodes
during radical prostatectomy and subsequent abor-
tion of procedure in African-American men.
In conclusion, during the study period, the overall
the utilization of ADT/expectant management de-
creased for all three groups; Hispanic and African-
American men were more likely to have received ADT/
expectant management compared with white men;
however, this racial and ethnic difference decreased
over time. Hispanic men were most likely to undergo
radical prostatectomy, and African-American men
were most likely to receive external beam radiation.
However, the utilization of external beam radiation
among African-American men decreased over the
study period. The utilization of brachytherapy and
combination therapy increased for all three groups,
with the greatest increase observed among white men.
To ascertain the implications of our findings for racial
and ethnic differences in the treatment of localized/
regional prostate carcinoma, further research will be
required to isolate possible racial and ethnic differ-
ences, like those observed in the current study, in the
patient-level and provider-level variables that may in-
fluence prostate carcinoma treatment decisions.
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